Aristotle Capital Boston buys $10,536,392 stake in PAREXEL International Corporation (PRXL)

PAREXEL International Corporation (PRXL) : Aristotle Capital Boston scooped up 5,596 additional shares in PAREXEL International Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 151,472 shares of PAREXEL International Corporation which is valued at $10,536,392.PAREXEL International Corporation makes up approximately 2.01% of Aristotle Capital Boston’s portfolio.

Other Hedge Funds, Including , Everpoint Asset Management added PRXL to its portfolio by purchasing 120,000 company shares during the most recent quarter which is valued at $8,347,200. PAREXEL International Corporation makes up approx 0.22% of Everpoint Asset Management’s portfolio.Blackrock Advisors boosted its stake in PRXL in the latest quarter, The investment management firm added 4,258 additional shares and now holds a total of 81,558 shares of PAREXEL International Corporation which is valued at $5,673,174. PAREXEL International Corporation makes up approx 0.01% of Blackrock Advisors’s portfolio.Redwood Investments boosted its stake in PRXL in the latest quarter, The investment management firm added 10,666 additional shares and now holds a total of 42,013 shares of PAREXEL International Corporation which is valued at $2,752,272. PAREXEL International Corporation makes up approx 0.24% of Redwood Investments’s portfolio.Msi Financial Services Inc boosted its stake in PRXL in the latest quarter, The investment management firm added 624 additional shares and now holds a total of 1,440 shares of PAREXEL International Corporation which is valued at $94,334.

PAREXEL International Corporation opened for trading at $68 and hit $68.5899 on the upside on Thursday, eventually ending the session at $68.34, with a gain of 0.46% or 0.31 points. The heightened volatility saw the trading volume jump to 2,79,468 shares. Company has a market cap of $3,614 M.

On the company’s financial health, PAREXEL International Corporation reported $0.94 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $0.93. The company had revenue of $538.60 million for the quarter, compared to analysts expectations of $532.59 million. The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 EPS.

Many Wall Street Analysts have commented on PAREXEL International Corporation. Shares were Downgraded by UBS on Sep 6, 2016 to ” Neutral” and Lowered the Price Target to $ 76 from a previous price target of $82 .Credit Suisse Initiated PAREXEL International Corporation on Jun 21, 2016 to “Outperform”, Price Target of the shares are set at $75.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company which provides a range of expertise in clinical research clinical logistics medical communications consulting commercialization and advanced technology products and services to the pharmaceutical biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management data management epidemiology health economics/outcomes research pharmacovigilance medical communications clinical pharmacology patient recruitment clinical supply and drug logistics post-marketing surveillance medical imaging services electronic data capture systems clinical trial management systems Web-based portals and other product development tools and services.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *